152626-75-0 Usage
Uses
Used in Pharmaceutical Research:
6-Methoxy-5-nitro(1H)indazole is used as a chemical compound in pharmaceutical research for its potential in developing new drugs. Its unique properties make it a promising candidate for creating innovative therapeutic agents.
Used in Antimicrobial Agents Development:
In the field of microbiology, 6-Methoxy-5-nitro(1H)indazole is used as an active ingredient for developing new antimicrobial agents. Its antibacterial and antifungal activities contribute to the fight against resistant strains and infections.
Used in Treatment of Inflammatory Disorders:
6-Methoxy-5-nitro(1H)indazole is being studied for its potential use as a treatment for various inflammatory disorders. Its capacity to modulate immune responses and reduce inflammation makes it a candidate for therapeutic intervention in conditions characterized by chronic inflammation.
Used in Neurological Disorders Treatment:
6-METHOXY-5-NITRO (1H)INDAZOLE is also being explored for its potential application in the treatment of neurological disorders. Its effects on neurological pathways and its ability to cross the blood-brain barrier make it a candidate for research into treatments for neurodegenerative diseases and other brain-related conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 152626-75-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,2,6,2 and 6 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 152626-75:
(8*1)+(7*5)+(6*2)+(5*6)+(4*2)+(3*6)+(2*7)+(1*5)=130
130 % 10 = 0
So 152626-75-0 is a valid CAS Registry Number.
152626-75-0Relevant academic research and scientific papers
PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
-
, (2012/02/01)
Compounds of the formula I or II: wherein X, m, Ar, R1 and R2 are as defined herein. The subject compounds are useful for treatment of IRAK-mediated conditions.
Design and synthesis of Rho kinase inhibitors (I)
Takami, Atsuya,Iwakubo, Masayuki,Okada, Yuji,Kawata, Takehisa,Odai, Hideharu,Takahashi, Nobuaki,Shindo, Kazutoshi,Kimura, Kaname,Tagami, Yoshimichi,Miyake, Mika,Fukushima, Kayoko,Inagaki, Masaki,Amano, Mutsuki,Kaibuchi, Kozo,Iijima, Hiroshi
, p. 2115 - 2137 (2007/10/03)
Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. A docking simulation using the ligand-binding pocket of the Rho kinase model helped to comprehensively understand and to predict the structure-activity relationship of the inhibitors. This understanding was useful for developing new Rho kinase inhibitors of higher potency and selectivity. We identified several potent platforms for developing the Rho kinase inhibitors, namely, pyridine, 1H-indazole, isoquinoline, and phthalimide.
